Verneris MR - Search Results

1

Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.

Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Baker J, et al. Among authors: verneris mr. Blood. 2001 May 15;97(10):2923-31. doi: 10.1182/blood.v97.10.2923. Blood. 2001. PMID: 11342413 Free article.

2

Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis.

Verneris MR, Kornacker M, Mailänder V, Negrin RS. Verneris MR, et al. Cancer Immunol Immunother. 2000 Aug;49(6):335-45. doi: 10.1007/s002620000111. Cancer Immunol Immunother. 2000. PMID: 10946816 Free PMC article.

3

Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells.

Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS. Kornacker M, et al. Among authors: verneris mr. Immunol Lett. 2001 Apr 2;76(3):169-73. doi: 10.1016/s0165-2478(01)00186-9. Immunol Lett. 2001. PMID: 11306144

4

Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis.

Kornacker M, Schlattner U, Wallimann T, Verneris MR, Negrin RS, Kornacker B, Staratschek-Jox A, Diehl V, Wolf J. Kornacker M, et al. Among authors: verneris mr. Int J Cancer. 2001 Nov;94(4):513-9. doi: 10.1002/ijc.1502. Int J Cancer. 2001. PMID: 11745437

5

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.

Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Verneris MR, et al. Biol Blood Marrow Transplant. 2001;7(10):532-42. doi: 10.1016/s1083-8791(01)70014-6. Biol Blood Marrow Transplant. 2001. PMID: 11760085 Free article.

6

Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.

Verneris MR, Baker J, Edinger M, Negrin RS. Verneris MR, et al. J Clin Immunol. 2002 May;22(3):131-6. doi: 10.1023/a:1015415928521. J Clin Immunol. 2002. PMID: 12078854 Review.

7

Advancing animal models of neoplasia through in vivo bioluminescence imaging.

Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, Negrin RS, Contag CH. Edinger M, et al. Among authors: verneris mr. Eur J Cancer. 2002 Nov;38(16):2128-36. doi: 10.1016/s0959-8049(02)00410-0. Eur J Cancer. 2002. PMID: 12387838 Review.

8

Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.

Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Edinger M, et al. Among authors: verneris mr. Blood. 2003 Jan 15;101(2):640-8. doi: 10.1182/blood-2002-06-1751. Epub 2002 Sep 26. Blood. 2003. PMID: 12393519 Free article.

9

Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence.

Negrin RS, Edinger M, Verneris M, Cao YA, Bachmann M, Contag ChH. Negrin RS, et al. Ann Hematol. 2002;81 Suppl 2:S44-5. Ann Hematol. 2002. PMID: 12611073 Review. No abstract available.

10

Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.

Verneris MR, Karimi M, Baker J, Jayaswal A, Negrin RS. Verneris MR, et al. Blood. 2004 Apr 15;103(8):3065-72. doi: 10.1182/blood-2003-06-2125. Epub 2003 Nov 20. Blood. 2004. PMID: 15070686 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

237 results

Search Page

Filters